To the Editor In their article, Gordon et al1 assessed the efficacy of transdermal estradiol and micronized progesterone in the primary prevention of depressive symptoms during menopause transition. They concluded that 12 months of transdermal estradiol associated with intermittent micronized progesterone was more effective than placebo in preventing the development of clinically significant depressive symptoms among initially euthymic perimenopausal and early postmenopausal women.
Hugon-Rodin J, Amand G, Plu-Bureau G. Safety of Estradiol Treatment in Perimenopausal Asymptomatic Women. JAMA Psychiatry. 2018;75(5):528–529. doi:10.1001/jamapsychiatry.2018.0615
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: